GSK, India’s Regulus Join To Make RNA-Based Drugs
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline has signed an agreement with India's Regulus Therapeutics, in a deal that could be worth as much as $600 million to the Indian biotech. The deal with GSK is for research into the Regulus specialty of RNA technology to discover microRNA-based drugs. The intention is to develop drugs to treat rheumatoid arthritis, inflammatory bowel disease and other diseases resulting from chronic inflammation. The deal gives GSK the option of licensing certain drug candidates. (Click here for more